Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
September 2016, Vol 7, No 8
September 2016, Vol 7, No 8
Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma
By
Lisa A. Raedler, PhD, RPh
Drug Updates
,
FDA Approvals, News & Updates
September 2016, Vol 7, No 8
Read Article
Increase in Drug Spending Largely Attributed to Rebates Pocketed by Pharmacy Benefit Managers
By
Robert Goldberg, PhD
Patient Advocacy
,
Policies & Guidelines
September 2016, Vol 7, No 8
Total drug spending in the United States, based on invoice prices, reached $425 billion in 2015, according to the IMS Institute for Healthcare Informatics report, “Medicines Use and Spending in the U.S.: A Review of 2015 and Outlook to 2020.” When adjusted for net price spending, $310 billion went to drug and biotech companies, but where the other $115 billion went is often omitted from media coverage.
Read Article
Gene Signature May Identify Nonresponders to Nivolumab
By
Alice Goodman
Personalized Medicine
September 2016, Vol 7, No 8
Immunotherapies have changed the way many patients with cancers, including patients with renal-cell carcinoma (RCC), are treated. Although some patients have a dramatic response to immunotherapies that appears to be sustained over the long-term, a large proportion of patients do not respond to treatment with programmed death (PD)-1 or PD ligand 1 (PD-L1) inhibitors. Therefore, the search continues for biomarkers that can help to determine which patients will likely respond to available checkpoint inhibitors, optimizing treatment selection.
Read Article
HF10 plus Ipilimumab Increases Response Rates in Metastatic Melanoma
By
Walter Alexander
Melanoma
,
Solid Tumors
September 2016, Vol 7, No 8
When combined with systemic ipilimumab (Yervoy), the investigational oncolytic viral immunotherapy HF10, a mutation of the HF strain of the herpes simplex virus type 1 (HSV-1), has local and systemic activity in patients with metastatic melanoma, said Robert Andtbacka, MD, CM, Huntsman Cancer Institute, Salt Lake City, during a poster presentation at the 2016 American Society of Clinical Oncology meeting. He added that HF10 substantially improves the response rate of ipilimumab alone and does not exacerbate ipilimumab toxicity.
Read Article
Collaborative Oncology Care Requires Good Mentoring, Self-Study
By
Alice Goodman
Collaborative Care
September 2016, Vol 7, No 8
Collaborative oncology care, which involves incorporating an advanced practitioner (AP) into an oncology practice, will help meet the growing burden of complex care and improve patient satisfaction.
Read Article
Lenalidomide Maintenance Therapy After ASCT Shows Survival Benefit in Patients with Multiple Myeloma
By
Walter Alexander
Hematologic Cancers
September 2016, Vol 7, No 8
A meta-analysis of overall survival (OS) in 3 clinical trials of lenalidomide (Revlimid) maintenance therapy after high-dose melphalan (Alkeran) and autologous stem-cell transplantation (ASCT) for multiple myeloma showed long-term disease control and prolonged OS. A slightly increased risk for a secondary primary malignancy is outweighed by the OS benefit, said lead investigator Philip McCarthy, MD, Roswell Park Cancer Institute, Buffalo, NY, in an oral presentation at the 2016 American Society of Clinical Oncology annual meeting.
Read Article
Venetoclax Shows Promising Efficacy in Relapsed or Refractory Acute Myelogenous Leukemia
By
Wayne Kuznar
Hematologic Cancers
September 2016, Vol 7, No 8
Venetoclax (Venclexta) monotherapy has significant clinical activity in patients with acute myelogenous leukemia (AML) whose disease has relapsed or is resistant to chemotherapy and in those deemed unable to tolerate chemotherapy, according to a new study. The overall response rate (ORR) for venetoclax in the phase 2 single-arm study was 19%, with complete remissions in some patients. This was the first study to examine venetoclax monotherapy in patients with relapsed or refractory AML or untreated AML who are unfit for intensive therapy.
Read Article
Adding Capecitabine to Gemcitabine Chemotherapy After Pancreatic Cancer Surgery Improves Survival
By
Walter Alexander
Pancreatic Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Adding capecitabine chemotherapy to gemcitabine after pancreatic cancer resection was associated with longer overall survival (OS) than gemcitabine chemotherapy alone, according to results from the European Study Group for Pancreatic Cancer (ESPAC)-4 clinical trial. For the small proportion of patients with pancreatic cancer who are candidates for surgery, adjuvant gemcitabine chemotherapy is the current standard of care worldwide, said John P. Neoptolemos, MD, Chair of Surgery, University of Liverpool, United Kingdom, during an oral abstract session at the 2016 American Society of Clinical Oncology annual meeting. “We thought that the combination of gemcitabine plus capecitabine…may be better than gemcitabine alone, and launched the phase 3 ESPAC-4 trial,” he stated.
Read Article
ESMO Consensus Guidelines for Metastatic Colorectal Cancer Offer Widely Expanded Recommendations
By
Walter Alexander
Colorectal Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Read Article
Nearly Half of Pancreatic Cancer Surgery Candidates Are Not Offered that Option
By
Charles Bankhead
Pancreatic Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Pancreatic cancer is the third leading cause of cancer-related death in the United States. Nearly half of patients with locoregional pancreatic cancer do not undergo potentially curative surgery, primarily because of nonclinical factors, according to the results of an analysis of data from the National Cancer Institute database by Amy T. Cunningham, MPH, a doctoral candidate at Thomas Jefferson University in Philadelphia, and colleagues.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma